Back to Journals » International Journal of Nanomedicine » Volume 14

A perspective on magnetic core–shell carriers for responsive and targeted drug delivery systems

Authors Albinali KE, Zagho MM, Deng Y, Elzatahry AA

Received 9 November 2018

Accepted for publication 15 January 2019

Published 6 March 2019 Volume 2019:14 Pages 1707—1723


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Govarthanan Muthusamy

Peer reviewer comments 2

Editor who approved publication: Dr Thomas J Webster

Kholoud E Albinali,1 Moustafa M Zagho,1 Yonghui Deng,2 Ahmed A Elzatahry1

1Materials Science and Technology Program, College of Arts and Sciences, Qatar University, Doha, Qatar; 2Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, iChEM, Fudan University, Shanghai, People’s Republic of China

Abstract: Magnetic core–shell nanocarriers have been attracting growing interest owing to their physicochemical and structural properties. The main principles of magnetic nanoparticles (MNPs) are localized treatment and stability under the effect of external magnetic fields. Furthermore, these MNPs can be coated or functionalized to gain a responsive property to a specific trigger, such as pH, heat, or even enzymes. Current investigations have been focused on the employment of this concept in cancer therapies. The evaluation of magnetic core–shell materials includes their magnetization properties, toxicity, and efficacy in drug uptake and release. This review discusses some categories of magnetic core–shell drug carriers based on Fe2O3 and Fe3O4 as the core, and different shells such as poly(lactic-co-glycolic acid), poly(vinylpyrrolidone), chitosan, silica, calcium silicate, metal, and lipids. In addition, the review addresses their recent potential applications for cancer treatment.

Keywords: magnetic, mesoporous, core–shell, drug carriers, active targeting, passive targeting, controlled release, targeted cancer treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]